Background: Xenotransplantation using fresh porcine corneas has been suggested as
| INTRODUC TI ON
Corneal transplantation is a standard treatment for corneal blindness, one of the most common causes for visual loss worldwide. [1] [2] [3] However, the need for human donor corneas has far exceeded supply, especially in developing countries. This issue is now emerging as a worldwide problem. 4 As substitutes to human donor corneas, porcine corneas are feasible options because their biophysical and optical properties are comparable to those of human corneas. In addition, breeding of pigs is easy without posing major ethical problems. Moreover, several genetically modified pigs are available to reduce immunologic responses. [4] [5] [6] [7] In fact, patients with fungal corneal ulcers have been successfully treated with lamellar keratoplasty (LKP) using acellular porcine corneal stromas. 8 However, there has been no clinical application of fresh (cellular) porcine corneas which are true xenotransplantation products defined by the World Health Organization (WHO).
9
Our recent progresses in corneal xenotransplantation research have overcome major obstacles in the attempt to introduce fresh porcine corneas as substitutes to human corneas. As a donor tissue, Seoul National University miniature pig (SNU pig, genetically unmodified) cornea has operable biophysical properties in human corneal bed, although it is thicker with flatter curvature than human cornea. Corneal endothelial cell density (ECD) of SNU pig younger than 72 months of age is comparable to that of human. In addition, ECD and Na-and K-dependent ATPase pump function could be well maintained up to 7 days when its cornea is processed by using preservation protocol same as that for human cornea. 10 Clinically applicable pig-to-non-human primate (NHP) corneal transplantation models have shown promising results in terms of efficacy and safety. Long-term survival of SNU pig corneal grafts has been achieved in rhesus recipients' corneal beds using only steroid-based immunosuppression for decellularized grafts in an anterior LKP model. 11 Anti-CD154 antibody-and anti-CD40
antibody-based immunosuppressive regimens have shown excellent effect on the survival of corneal xenografts in a penetrating keratoplasty (PKP) model 12 and a deep anterior lamellar keratoplasty (DALK) model, 13 respectively. Moreover, combination of certain commercially available immunosuppressive drugs has also
shown promising results in a PKP model (not published). Regarding concerns about transmission of porcine endogenous retrovirus (PERV), no PERV transmission is evident in long-term follow-up blood and tissue samples in various pig-to-NHP corneal transplantation models. 14 These promising preclinical data have encouraged us to prepare for the next step, a clinical trial.
The first report on potential cross-species transmission of PERV 15 has raised growing concern about the risk of transmission of known or as yet unrecognized xenogeneic infectious agents from animals to human. Considering that cellular porcine corneal grafts are not exempted from xenozoonosis, key ethical and regulatory requirements for corneal xenotransplantation clinical trials are essentially the same as those for other organ xenotransplantation clinical trials. [16] [17] [18] To meet international consensus, we have standardized all proceedings and developed a relevant clinical trial protocol. Accordingly, here we report the detailed protocol for the first corneal xenotransplantation clinical trial in patients with corneal opacity, corneal perforation, or impending corneal perforation.
the protocol have been modified with reference to comments provided by ophthalmologists and multidisciplinary experts, including an infectionist, an organ transplantation specialist, a clinical pharmacologist, a neuropsychiatrist, a laboratory medicine doctor, and a microbiologist.
Results: Two patients with bilateral legal corneal blindness (best-corrected visual acuity ≤20/200 in the better eye and ≤20/1000 in the candidate eye) or with (impending) corneal perforation will be enrolled. During the screening period, participants and their family members will have two separate deep consideration periods before signing informed consent forms. Each patient will undergo corneal xenotransplantation using fresh corneas from Seoul National University miniature pigs. Commercially available immunosuppressants will be administered and systemic infection prophylaxis will be performed according to the program schedule. After transplantation, each patient will be monitored at a specialized clinic to investigate safety up to 2 years and efficacy up to 1 year.
Conclusions:
A detailed clinical trial protocol for the first corneal xenotransplantation reflecting the global guidelines is provided.
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| International consensus for undertaking xenotransplantation
To conduct a regulated and transparent corneal xenotransplanta- 
| Special considerations when undertaking corneal xenotransplantation
Although we have provided adequate safety and efficacy data through rigorous preclinical corneal xenotransplantation studies using the most relevant animal models, 11-14,21 these do not guarantee no risks, including graft rejection, inadequate graft function, and transmission of infectious diseases to human recipient. To assess the risk vs benefit of corneal xenotransplantation, corneaspecific issues should be considered, including the following: (a)
Corneal blindness is not a life-threatening disease and (b) the eye is an immune-privileged organ to some extent. 22 Moreover, considering that this is the first corneal xenotransplantation procedure using fresh porcine cornea, potent immunosuppression will be applied to participant, and there has been no information about actual harm to human recipients, primary objective of this study was designated as safety in corneal xenotransplantation procedure and related immunosuppression. Two participants will be enrolled in this initial clinical trial.
| Development of a relevant clinical trial protocol
Reflecting special issues described above, we have developed a relevant protocol for the first corneal xenotransplantation clinical trial in Korea. Overall concepts are based on IXA consensus statement on conditions for undertaking clinical trials of xenocorneal transplantation 20 and porcine islet cell transplantation. 23, 24 They were slightly modified in accordance with circumstances in Korea.
To make a strict and flawless protocol, we had meetings more than 10 times during 2 years. We sought opinions from multidisciplinary consulting boards and a contract research organization (C&R 
| RE SULTS

| Overall study design
This is a non-randomized, open-label, single-center, and investigatorinitiated phase I clinical trial to investigate safety and efficacy of corneal xenotransplantation in patients with corneal opacity, corneal perforation, or impending corneal perforation. Two patients will be enrolled at one hospital (Seoul National University Hospital, Seoul, Korea) and undergo partial or full-thickness corneal xenotransplantation using corneas from SNU pigs. Commercially available immunosuppressants will be administered according to the program schedule. Each patient will visit a specialized ophthalmic clinic for comprehensive postoperative monitoring to investigate safety and efficacy of the procedure for up to 2 years ( Figure 1 ). The patient's spouse or sexual partners will also be monitored to evaluate evidence of xenozoonosis.
| Study objectives
| Primary objective
The primary objective is to provide evidence of safety of corneal xenotransplantation determined by adverse reactions and changes in vital signs and laboratory test profiles during the period of clinical trial.
| Secondary objective
The secondary objective is to investigate the survival of porcine corneal grafts in human corneal recipients' beds at 1 year after transplantation. This will be quantitatively evaluated by opacity, edema, and neovascularization on slit-lamp examination.
| Exploratory objectives
The exploratory objective is to explore the number of graft rejection episodes, the number of administration, and the type of immunosuppressive drugs other than those described in the program schedule.
| Study participants
In this single-center clinical trial, two subjects will be enrolled This guideline of visual acuity can be exempted for participants who require emergency operation for an actual or impending corneal perforation.
| Screening and informed consent
Screening period starts from 6 months before surgery. Our medical team will check participant's vital signs, general health status, and medical history including previous surgeries, concurrent ophthalmic and systemic diseases, and topical and systemic medica- During the screening period, the participant and his/her family members will be informed by the investigator(s) about the aims of this study, corneal transplantation procedures, potential benefits, alternative treatment options, possible AEs, possible hazards to which F I G U R E 1 Overall study design. Patient screening starts from 6 mo before xenotransplantation. Two separate deep consideration periods will be given to participants and their family members between signing two different informed consent documents (V1~V3). Immunosuppression starts from 7 d before operation (V4-1~V4-2). Corneal transplantation using porcine donor cornea (D0) and immediate postoperative intensive monitoring (V5-1~V5-9) will be performed under hospitalization. Each participant will be monitored at a specialized outpatient ophthalmic clinic as described in the program schedule to obtain safety data (primary objective) up to 2 y and efficacy data (secondary objective) up to 1 y post-transplantation (V6~V26). V, visit he/she will be exposed, who will access to the patient's data, and what provisions are made for compensating those who suffer harm from trial participation. It will be emphasized that the participation is voluntary, the patient is allowed to withdraw further participation in the trial whenever he/she wants, and such withdrawal from the trial will not prejudice the patient's subsequent care. The participant and family members will also be informed of their responsibilities, including attendance for continuous examination and storage of blood/ tissue samples for a certain time even after he/she withdraws from the study.
Consent forms are IRB-approved. Each participant and his/her family members will be asked to read and review the documents.
Particularly, there will be two separate deep consideration periods between signing two different informed consent documents (before and after screening tests). Two separate comprehensive counseling by an experienced neuro psychiatrist will be given. Moreover, if necessary, other neutral advocate ophthalmologists will explain the study in detail again. Each copy of the informed consent documents will be given to the participant and family members for their records (Table 2 ).
| Preparation of donor porcine cornea
Porcine corneas will be obtained from adult inbred designated pathogen-free SNU pigs kindly donated by Dr. YB Kim. These pigs have been bred at the Center for Animal Resource Development, Seoul National University College of Medicine.
To ensure adequate procurement, processing, preservation, and storage, guidelines of the European Eye Bank Association on the preparation of human corneal tissue will be followed with slight modification as described elsewhere. 10 Briefly, enucleation of porcine eyeballs is performed according to standard techniques.
Enucleated eyeballs are soaked in 5% betadine solution for a minute and irrigated with 10% cefazolin and 2% gentamycin solution
TA B L E 1 Inclusion and exclusion criteria
Inclusion criteria
Patients who are 19 y old or more.
Patients who have been diagnosed with legal blindness, which is defined as best-corrected visual acuity (BCVA) of 20/200 or less in the better eye. BCVA in the eye which requires a transplant should be 20/1000 or less. This guideline of visual acuity can be exempted in participants who require emergency operation of patch grafts in circumstances of an actual or impending corneal perforation.
Patients who have been diagnosed with a corneal impairment that cannot be cured with any other method except corneal transplantation.
Patients, who have no potential for visual restoration, can be enrolled when they want to reduce ocular pain or to relieve cosmetic concern.
Patients who have an actual or impending corneal perforation, which would be resulted in serious consequences if the corneal transplantation is delayed until when an allograft is available.
Patients who understand the risks and consequences of the procedure, including the need for compliance with long-term follow-up plan and a variety of hospital visits and surveillance testing described on the protocol for clinical trial.
Exclusion criteria
Patients, who do not meet the inclusion criteria described above and have specific conditions as follows, will be excluded in this study.
Patients who have been diagnosed with keratoconus.
Women who are pregnant, have a plan for pregnancy or are breast-feeding a baby.
Patients who have been diagnosed with mental retardation or have been mentally incapacitated, at the discretion of the investigator.
Patients who have a hypersensitivity to or a contraindication for drugs which will be used in this study.
Patients who have serious concomitant systemic disorder, that compromises the safety of the patient, such as: Full documentation is filled out to inform tissue characterization, including enucleation to preservation time, gross examination of the cornea, findings of slit-lamp examination, endothelial evaluation by a specular microscope, and culture report.
| Surgical procedure: corneal xenotransplantation
Basic surgical techniques are exactly the same as those of corneal allotransplantation. The operation will be performed under general anesthesia while the participant is hospitalized.
| Partial thickness corneal transplantation
Portion of the recipient's cornea including lesion is incised and removed. A donor porcine cornea which is maintained in a Barron artificial anterior chamber (Katena Products Inc., Denville, NJ, USA) is manually dissected by using a crescent knife (Alcon Surgical, Fort Worth, TX, USA) to the same thickness and size as the removed recipient cornea. The xenograft is placed in the recipient bed and secured with 10-0 nylon sutures.
| Full-thickness corneal transplantation
A donor cornea is punched out as a full-thickness graft using a Barron vacuum donor cornea punch (Katena Products Inc.). Full-thickness central portion of the cornea is incised from a recipient's eye using a
Hessburg-Barron vacuum trephine (Katena Products Inc.). The por-
cine corneal graft is placed in the recipient bed and secured with 10-0 nylon sutures. 
| Perioperative medical treatment
| Immunosuppressive regimen
In this study, commercially available immunosuppressive agents will be administered. A combination of certain systemic immunosuppressive drugs (rituximab, basiliximab, tacrolimus, immunoglobulin, and corticosteroid) has already been proven to be effective through a clinically applicable pig-to-non-human corneal xenotransplantation study (data not shown). This met the minimum requirement for preclinical efficacy to justify initiating a clinical trial by the IXA. 
| Infection prophylaxis
Considering potent systemic immunosuppression scheduled in this study, meticulous infection prophylaxis which is applied to human solid-organ transplantations such as kidney transplantation is mandatory. In addition to routine topical and systemic antibiotic prophylaxis for corneal transplantations, disease-specific regimens targeting cytomegalovirus infection, Pneumocystis pneumonia, and tuberculosis will be administered according to results of screening tests.
| Visits, tests, data collection, and data analysis
Overall timeline is divided into four periods as follows: (a) On each visit after transplantation, the participant is required to report any AEs. He/she will undergo comprehensive systemic and ocular investigations to evaluate the safety and efficacy of corneal xenotransplantation and immunosuppression. Various specimens will be regularly collected to monitor T-/B-cell responses, changes in anti-Gal and donor pig-specific antibodies, existence of PERV materials in blood samples, and complement C3a level in aqueous humor. These have been proven to be valuable markers for anticipating clinical courses and confirming xenozoonosis in pig-to-NHP corneal xenotransplantations. [11] [12] [13] [14] In particular, a multidisciplinary team (ophthalmologists, a neuropsychiatrist, an infectionist, a clinical pharmacologist, and an organ transplants specialist) consultation will be given to assess primary and secondary endpoints comprehensively. All data will be recorded on specific case report forms (CRFs).
| Primary endpoint (safety)
To evaluate safety of corneal xenotransplantation, any AEs and significant changes in vital signs and laboratory test results will be mon- suggesting xenozoonosis is considered as an SAE regardless of its severity. The degree of certainty about causality between corneal xenotransplantation procedures or drugs used and AEs will be categorized by using modified WHO-UMC causality assessment system as follows: certain, probable/likely, possible, unlikely, none, and unassessable.
| Secondary endpoint (efficacy): assessment of graft rejection
As a landmark of efficacy of corneal xenotransplantation, the survival of each xenograft will be monitored and the final survival at 1 year post-transplantation will be recorded on CRFs. Graft rejection is defined based on the sum of grades for opacity, edema, and vascularization adopted from previous reports. 
| Statistical methods
As only two participants will be enrolled in this study, a detailed description rather than specific statistical analyses about demographic data and evaluation variables for safety and efficacy of corneal xenotransplantation will be given for each participant.
| D ISCUSS I ON
The aim of the present report is to share a study protocol to con- Because of wider community risks, especially xenozoonosis, global consensus is that there should be no xenotransplantation in the absence of proper regulatory oversight by the government of the country. [16] [17] [18] [19] [20] This regulation should have a legal basis with powers to ban unregulated xenotransplantation procedures. In addition, transparency of the study is emphasized, including relevant design of the trial, full publication of data, independent experts' advice, and timely independent data review. 18 To meet these global consensus and requirements, we have closely communicated with the rele- Post-transplantation D7, W4 ± D4, W8 ± D4, W12 ± D4 pro re nata thereafter firmly established in Korea, this clinical trial will follow its guidance/ guidelines and trial records, data, and repositories of samples from source pigs and recipients prior to and following xenograft transplantation will be managed as described in the law for prolonged periods of time. Data and Safety Monitoring Board has been organized to inspect protocol adherence, patient eligibility, intensity of follow-up, and regular reviews of the data as the trial progresses by independent expert panels. A report describing results of the study will be submitted to a peer-reviewed journal. Where permitted by patient data protection standards, data will be published and shared together with the publication of study results.
In summary, we have developed a protocol for the first regulated clinical trial of corneal xenotransplantation in Korea based on global consensus and guidelines. Here, we report the detailed protocol and share it with xenotransplantation-related researchers worldwide to gain academic recognition. We hope this protocol will be a cornerstone of conducting regulated and transparent clinical trials of corneal xenotransplantation in the future.
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